article thumbnail

JPM24, Day 1: Moderna touts $6.7B in '23 sales; Bluebird has cash on hand to last until early 2025

Fierce Pharma

Morgan Healthcare Conference kicked off in San Francisco, EY released its annual report on the industry's dealmaking firepower. | Morgan Healthcare Conference kicked off in San Francisco, EY released its annual report on the industry's dealmaking firepower. As the J.P. As the J.P.

article thumbnail

Vaccine Sales Drop for Moderna in 2023 With Growth Expected by 2025

Pharmaceutical Commerce

At the 42nd annual JP Morgan Healthcare Conference, Moderna said new product launches later this year will return the company to sales growth in 2025.

Sales 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Building Trust Through Healthcare Influencer Partnerships

LEVO Health

Healthcare organizations are increasingly partnering with influencers to build trust with their audience and expand their reach. By collaborating with influencers, healthcare brands can share their message with humanity, connect with consumers personally, and establish credibility within their target communities.

article thumbnail

Highlights from The Data Ecosystem in 2025

Prognos Health

Datavant , the leader in helping healthcare organizations securely connect their data and a Prognos Health partner, recently held its Future of Health Data Summit in Washington DC. Summit is a wonderful opportunity for them to share their learnings with the broader healthcare ecosystem.”

article thumbnail

Aneesh Chopra: VBC Will Bring ‘Radical’ Transparency to Healthcare for These 3 Reasons

MedCity News

Aneesh Chopra, president and co-founder of CareJourney, predicted accelerated enrollment in value-based care models in 2024 and 2025.

article thumbnail

Genetic Medicines Biotech Dyne Pulls In $345M for Clinical Tests of Muscle Drugs

MedCity News

Morgan Healthcare Conference, CEO Joshua Brumm said Dyne’s existing cash combined with the new capital is expected to last through 2025—well beyond the next key milestones for both therapeutic candidates. At the J.P.

article thumbnail

MSD’s maternal health initiative passes big milestone

pharmaphorum

A $650 million programme set up by pharma group MSD to help prevent maternal mortality and improve health equity around the world has reached over 30 million women, easily outpacing its target of 25 million by 2025. In the US and Canada, where MSD is known as Merck & Co, it runs under the Merck for Mothers banner.

Pharma 57